Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Claim 1 specifically pertains to a compound represented by Formula (I). GlobalData’s report on Enanta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Enanta Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Enanta Pharmaceuticals's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11858945B2) discloses a compound represented by Formula (I) and its various derivatives and pharmaceutically acceptable salts. The patent claims cover a range of compounds with specific structural characteristics, including those represented by Formula (III-1), (V), (X), and others. Additionally, the patent includes claims for pharmaceutical compositions comprising the disclosed compound and methods for treating or preventing virus infections, specifically coronavirus infections such as those caused by 229E, NL63, OC43, HKU1, SARS-CoV, or MERS coronavirus. The methods involve administering an effective amount of the compound to the subject, with a focus on inhibiting viral 3C protease or viral 3CL protease to combat the infection.
Furthermore, the patent extends to methods for treating respiratory disorders in subjects by administering the disclosed compound orally, subcutaneously, intravenously, or by inhalation. The patent emphasizes the therapeutic potential of the compound in addressing respiratory disorders and virus infections, particularly those caused by coronaviruses. With a specific focus on inhibiting viral proteases and treating respiratory conditions, the patent provides a comprehensive framework for utilizing the compound in pharmaceutical compositions for therapeutic purposes. The patent's claims highlight the compound's versatility in treating various virus infections and respiratory disorders, positioning it as a valuable asset in the field of antiviral and respiratory therapeutics.
To know more about GlobalData’s detailed insights on Enanta Pharmaceuticals, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
